GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine

GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine#Biopharma #Receives #MFDS #Approval #World039s #Recombinant…

Quantum BioPharma stock soars on removal of uncertainty related to going concern

Quantum BioPharma stock soars on removal of uncertainty related to going concern#Quantum #BioPharma #stock #soars #removal…

Arbutus Biopharma: A Wing And A Prayer

Arbutus Biopharma: A Wing And A Prayer #Arbutus #Biopharma #Wing #Prayer

Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline

Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline#Sutro #Biopharma #stock #hits #52week #sharp…

Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator

Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator #Xeris #Biopharma #Risk #Excitement #Solid #Revenue #Generator

WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025

WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025#WuXi #XDC #Wins #Multiple #Awards #AsiaPacific…

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive #Theravance #Biopharma #Clinical #Progress #Attractive

AEON Biopharma executes reverse stock split to comply with NYSE standards

AEON Biopharma executes reverse stock split to comply with NYSE standards#AEON #Biopharma #executes #reverse #stock #split…

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory…

Hansa Biopharma AB (HNSBF) Q4 2024 Earnings Call Transcript

Hansa Biopharma AB (HNSBF) Q4 2024 Earnings Call Transcript #Hansa #Biopharma #HNSBF #Earnings #Call #Transcript

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return By Reuters

By Deena Beasley SAN FRANCISCO (Reuters) – The biopharmaceutical industry is aiming for a 2025 reversal…

Argent BioPharma Ltd. Raised US$4,500,000 By Investing.com

PERTH, Australia, Jan. 7, 2025 /PRNewswire/ — Argent BioPharma (ASX:RGT) (OTCQB:RGTLF),  a clinical-stage biopharmaceutical company addressing…

Sutro Biopharma: I Don’t Buy That Their Pipeline Is Worthless (NASDAQ:STRO)

This article was written by Follow I have my PhD in biochemistry and have worked for…